Courtesy of the Ottawa Business Journal

Tetra Bio-Pharma raised a few extra million dollars this week, as the Orléans-based firm announced an expansion into the European medical cannabis market.

The local cannabinoid drug developer closed a bought-deal financing round of $11.5 million on Monday after upsizing its original plans to raise $8 million. Echelon Wealth Partners served as underwriters on the round.

Tetra says it intends to use the round to advance clinical testing on a cannabis-based pain-relief therapy for cancer patients.

On Tuesday, the firm also announced an expansion into the European cannabis market. The firm’s development and manufacturing partner PS Innovations is seeking European regulatory approval on its inhaler devices, which purport to mitigate pain for medical patients through a blend of cannabis strains.

“This is significant for Tetra since there are a number of European countries, with Germany at the forefront, where medical cannabis has been legalized,” said Bernard Fortier, Tetra’s CEO, in a statement.

Shares of Tetra Bio-Pharma (TSX-V:TBP) closed at $0.92 on Tuesday, an increase of roughly 10 per cent since the week began. That’s well below the firm’s all-time high of $1.71, however, which it hit in January of this year. Shares of many Canadian cannabis firms took a tumble around that time.

Chestnut Park appoints luxury executive as COO

Chestnut Park appoints luxury executive as COO

Nicolle Scavuzzo has joined Chestnut Park Real Estate as Chief Operating Officer. Her career has included senior roles in brand  marketing, customer experience and loyalty, CRM technology and training  at Four Seasons Hotels & Resorts, American Express, and...

“Peerage is the epitome of entrepreneurial spirit and has consistently supported and encouraged Baker’s tradition of thinking outside the box. This has resulted in Baker taking bold steps in technology innovation, increasing sales and tremendous growth in revenue.”

Barbara Lawlor,
CEO and President,
Baker Real Estate Incorporated, Brokerage

“Peerage Capital has had a dramatic influence on cultivating an entrepreneurial spirit and focus at Chestnut Park. There is a pervasive encouragement to grow, but on our terms and time lines. Success is recognized and rewarded. Help is available if needed. Peerage proveds the perfect combination of independence and security.”

Chris Kapches,
LLB, President and CEO, Broker of Record,
Chestnut Park Real Estate Limited, Brokerage

“We were looking for a like-minded group to partner with to assist with our continued success. We found that in Peerage Realty Partners. We remain independent and retain our identity while being able to take advantage of the benefits of being part of the Peerage Realty Partners group.”

Catherine Deluce,
Founder and Chair,
Chestnut Park Real Estate Limited, Brokerage

“From the inception of our partnership, Peerage made it clear by both their words and actions that while they would always be available to discuss business strategies or financial assistance, they trusted us to manage our company competently, ethically and efficiently. They are partners in every sense of the word.”

Michael Schaenen,
Senior Partner,
ARS Investment Partners,

“Peerage provided us with all the resources and support to allow us to grow at lightning speed and with precision. Partnering with Peerage Capital has made us a force to be reckoned with in the real estate industry.”

Mary Johnson,
Vice President,
StreetCity Realty Inc., Brokerage

“Peerage Capital provides ARS Investment Partners with the right balance of operating autonomy and strategic support. Peerage recognizes and respects the expertise and judgment of the ARS management team, and allow us to do what we do best.”

Stephen Burke,
Managing Partner,
ARS Investment Partners

“Through our partnership with Peerage we are able to retain our independence while benefitting from the support of their seasoned senior management team and having access to Peerage’s valuable network.”

Rob Furse,
Echelon Wealth Partners


Peerage Capital
1325 Lawrence Avenue East
Suite 200
Toronto, ON
M3A 1C6
T: 416-840-4686
F: 416-934-7459